tweetindex
FR

Sanam Loghavi, MD صنم لغوی 🔬🧬 ✓

@sanamloghavi · Houston, TX · joined 13 Mar 2015

Hematopathologist/Molecular Pathologist (endangered species) Director of ECOG-ACRIN Leukemia Bank @mdandersonnews - Editor in Chief #ASHImageBank

22 310Followers
821Following
11 020Posts total
53.6KViews on collected posts

Derniers posts

A molecular pathologist’s mid-life crisis fix!! @illumina Better than a @Porsche 😉 https://t.co/qOnFrUGIRI
3.8K views · 96 likes · 6 reposts · 4 replies Open on X →
The waning moon and Venus putting on a show and welcoming our hematology friends to #SOHO26 this morning in #Houston. Wishing everyone a fun and productive meeting! Let the madness begin … https://t.co/FGholerxtF
2.1K views · 52 likes · 3 reposts · 2 replies Open on X →
Join us for the second Women in Hematology Conference Nov 6-7 in Austin TX. Register here https://t.co/1Nz3zZbFCT @_MDEducation @DrKrinaPatel @SoniSmithMD https://t.co/3aTcb41E5K
3.6K views · 64 likes · 11 reposts · 0 replies Open on X →
Looking forward to speaking at @TheIACH about the practical applications of contemporary hematopathology 3.6K views · 35 likes · 7 reposts · 1 replies Open on X →
@sanamloghavi @ljmedeirosMD @Human_Pathology I can’t access these and they look solid. Can you pretty please send me the issue. 570 views · 3 likes · 0 reposts · 0 replies Open on X →
Finally.. I'd like say how grateful we are to each and every one of the authors who contributed to this issue and shared their expertise... what a privilege to be able to host this hemepath/leukemia soirée. I admire you all so much!! https://t.co/6XwbNhP1Sf
1K views · 23 likes · 2 reposts · 1 replies Open on X →
and last but certainly not least.. the issue would not be complete without this fantastic review on the emerging role of AI in diagnostics in myeloid malignancies by Pravin Patel and Olga Pozdnyakova 4/14 🧵https://t.co/hTsKsqwTS2 https://t.co/adfujAVTOM
893 views · 10 likes · 2 reposts · 1 replies Open on X →
Next up.. cell therapies,@ImanSarami & @ljmedeirosMD walk us through CAR-T cell therapy & its complications, and the role of the pathologist in their diagnosis 13/14 🧵 https://t.co/DhcuCqGgtj https://t.co/oOBYIAXQsM
1K views · 22 likes · 4 reposts · 1 replies Open on X →
Who better than the queen of single cell sequencing in AML.. @lindemilesphd to write about the application of single-cell technologies to AML 😉 with Annabelle Anandappa and @drwenbin_xiao they write this marvelous piece of work.. please check it out.. you will love this one ht
3.7K views · 20 likes · 3 reposts · 1 replies Open on X →
Next up.. everyone's favorite topic: MRD.. A master review by the one and only @jadothm, George Mason and Ameya Hanamshet a, on Multimodal MRD detection in AML: From technology to clinical integration .... Please do yourself a favor and read this.. it is gold! 11/14 https://t.
1.1K views · 21 likes · 2 reposts · 1 replies Open on X →
G Tang, Q Wei, M Klausner, YS. Zou and @gokcetoruner write about Optical genome mapping (OGM) and how it has improved our detection of clinically relevant CG alterations in myeloid neoplasms. https://t.co/i19SOskQL3 10/14🧵 https://t.co/WueqIoB3TF
967 views · 14 likes · 2 reposts · 1 replies Open on X →
The final 6 reviews address the technologies that have made the precision medicine era in acute leukemia possible. @JenMarvinPeek , @Daver_Leukemia @TapKadia , @GhayasIssa F Ravandi, C. DiNardo, open this section with a clinically oriented review of advanced molecular https://t.
1.2K views · 24 likes · 5 reposts · 1 replies Open on X →
Pivoting to CMML... @GMontalbanBravo & yours truly write about oligomonocytic CMML... if you know me at all.. you know I've been obsessed with this topic for a while.. so this was quite satisfying to write 😉 https://t.co/C34kj3Sp30 8/14🧵 https://t.co/blMiRmJFnz
1K views · 17 likes · 4 reposts · 1 replies Open on X →
Next up is one of my favorites: Myeloid Sarcoma. The one & only @AkEisfeld & @ljmedeirosMD write a tour de force on MS, proposing a paradigm shift in the way we think about this disease! spoiler alert: RAS RAS RAS https://t.co/xXIAGvOafA This one has a special place in my htt
3.9K views · 20 likes · 6 reposts · 1 replies Open on X →
Next up, Derek Loneman, Valentina Nardi and Rob Hasserjian write a practical guide to contemporary AML diagnosis and classification. Their review traces the evolution of AML classification from the FAB to present. Its soooo good!! @MassGeneralNews https://t.co/0KXGB4ooFC 6/14🧵 h
1.5K views · 40 likes · 11 reposts · 4 replies Open on X →
Next, AML in the spotlight , First @KMirza , Julia Anderson-Calleja, et al, sprovide a beautiful depiction of how the cytomorphologic findings correlate with genotype. Major shoutout to all pathologist out there 🔬.. single cell sequencing is hot and all... but have you every htt
1.6K views · 19 likes · 8 reposts · 1 replies Open on X →
Next, @SaWangMD and Vicky Leventaki take us through an MPAL tour emphasizing the practical application of lineage assignment criteria & discuss the genomic underpinnings of this MPAL, including ZNF384r, BCL11B, BCR::ABL1 and more.. https://t.co/M3psQz6T5X 4/14🧵 https://t.co/s
1.2K views · 13 likes · 6 reposts · 1 replies Open on X →
Next, Wei J. Wang, @JoeKhouryMD @ljmedeirosMD , Hong Fang and Wei Wang wrote about T-ALL, with a practical approach to diagnosis, differential diagnosis, and subtype classification using flow and IHC. https://t.co/6rwoht1wxQ 3/14🧵 https://t.co/bLUc8FwOxA
1.1K views · 21 likes · 3 reposts · 1 replies Open on X →
First up, a fantastic review B-ALL with a focus on molecular classification by @r_sazevedo and @NicholasShortMD 2/14 🧵 https://t.co/9pUe1ao3xq https://t.co/Dmw29TvD11
2.3K views · 47 likes · 11 reposts · 1 replies Open on X →
Excited and proud to share our special issue on #Leukemia that @ljmedeirosMD & I put together for @Human_Pathology We brought together incredible experts to write about the latest in the field. 13 articles, each one #hemepath GOLD💎! 1/14🧵 Starting with our intro to the issue h
17.4K views · 124 likes · 40 reposts · 11 replies Open on X →

Face aux comptes de taille comparable

20 posts des 90 derniers jours, à côté de la tranche de 10K–100K abonnés. diffusé bien au-delà de son propre public, et ce public réagit.

Vues médianes1 352ce compte924médiane pour 10K–100K
Portée, %6.06%ce compte3.62%médiane pour 10K–100K
Engagement, %2.16%ce compte1.52%médiane pour 10K–100K
IndicateurCe compteMédiane pour 10K–100KRapport
Vues médianes par post1 3529241.46×
Portée (vues ÷ abonnés)6.06%3.62%1.67×
Taux d'engagement2.16%1.52%1.42×

Autres comptes de cette tranche →   Comparer avec un autre compte →   Comment ces repères sont établis →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.9K15 Aug
1K
1.2K
967
1.1K
3.7K
1K
893
1K
570
3.6K3 Sep
3.6K7 Sep
2.1K9 Sep
3.8K10 Sep

Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.71%15 Aug
2.16%
2.49%
1.76%
2.23%
0.68%
2.67%
1.46%
2.48%
0.53%
1.19%3 Sep
2.15%7 Sep
2.75%9 Sep
2.81%10 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes66.6%685 in total
Reposts13.2%136 in total
Replies3.4%35 in total
Quotes1.3%13 in total
Bookmarks15.5%159 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Comptes similaires